WORCESTER, Mass., July 15, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) today announced its receipt of a decision by the NASDAQ Listing Qualifications Panel, which granted the Company’s request for continued listing of the Company’s common stock on The NASDAQ Stock Market on an interim basis, subject to certain conditions subsequent which are described in the Form 8-K Current Report filed by the Company with the Securities and Exchange Commission on EDGAR (www.sec.gov) earlier today.
